CN112370470A - Microecological preparation for reconstructing intestinal microecology - Google Patents

Microecological preparation for reconstructing intestinal microecology Download PDF

Info

Publication number
CN112370470A
CN112370470A CN202011294300.7A CN202011294300A CN112370470A CN 112370470 A CN112370470 A CN 112370470A CN 202011294300 A CN202011294300 A CN 202011294300A CN 112370470 A CN112370470 A CN 112370470A
Authority
CN
China
Prior art keywords
intestinal
preparation
microecological
lactobacillus
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011294300.7A
Other languages
Chinese (zh)
Other versions
CN112370470B (en
Inventor
周平红
蔡明琰
石国良
王羽娟
林卫军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomson Biotech Xiamen Pte Ltd
Zhongshan Hospital Fudan University
Original Assignee
Thomson Biotech Xiamen Pte Ltd
Zhongshan Hospital Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomson Biotech Xiamen Pte Ltd, Zhongshan Hospital Fudan University filed Critical Thomson Biotech Xiamen Pte Ltd
Priority to CN202011294300.7A priority Critical patent/CN112370470B/en
Publication of CN112370470A publication Critical patent/CN112370470A/en
Application granted granted Critical
Publication of CN112370470B publication Critical patent/CN112370470B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a microecological preparation for reconstructing intestinal microecology. Specifically, the invention provides a microecological preparation, which comprises a strain, sodium alginate, konjac mannan, xylan, L-arabinose and chitosan; the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof. The microecological preparation can remarkably improve the recovery and reconstruction of intestinal microecology after intestinal operation through intestinal preparation, improve the intestinal microecological imbalance of the intestinal operation, and improve the side effects of diamine oxidase level increase, intestinal mucosa permeability increase, intestinal mucosa barrier damage and the like.

Description

Microecological preparation for reconstructing intestinal microecology
Technical Field
The invention relates to the field of biological preparations, in particular to a microecological preparation for reconstructing intestinal microecology.
Background
The intestinal micro-ecosystem refers to an ecosystem formed by the intensive inhabitation of different flora on the surface of intestinal mucosa of a human body and the inhabitation environment of the intestinal mucosa. It is the most important of the five microecosystems of human body, such as gastrointestinal tract, oral cavity, genitourinary tract, skin and respiratory tract, and is the most studied system. The intestinal micro-ecosystem is widely involved in a plurality of physiological and pathological activities such as metabolism, mucosal barrier, immunoregulation and the like of a human body, and is an important barrier for maintaining the health of the human body. These colonizing intestinal flora are "resident" in the intestinal tract and play a vital role in regulating the health of the human intestinal tract. .
The microbial ecological agent is a combined agent prepared by normal microbial flora beneficial to a host and metabolites thereof or growth promoting substances thereof, and the like, and can adjust and maintain the microbial ecological balance of the host through the actions of biological barriers, adhesion planting and the like, thereby improving the health state of the host.
In the enterogastroscopy, in order to obtain a clear visual field and ensure the high-quality examination, an intestinal preparation strategy is not selected before an operation, the intestinal preparation is to clean the intestinal tract before an enteroscopy or an abdominal operation, if excrement is left, the intestinal tract is not clearly seen during the enteroscopy, the examination effect cannot be achieved, and the gastrointestinal tract contents pollute the abdominal cavity and influence the operation visual field during the abdominal operation. In terms of medicament selection, the currently clinically strong recommended medicaments for intestinal tract preparation are magnesium sulfate and polyethylene glycol. During the process of cleaning the intestinal tract, damage to the intestinal mucosa and interference with the intestinal microecosystem are inevitable, and even in some cases of inflammatory bowel disease, the preparation of the intestinal tract may induce relevant clinical symptoms. Reports show that after intestinal tract preparation of healthy people, the abundance of intestinal flora is rapidly reduced, and a longer time is needed for recovering normal level. Compared researches on intestinal flora before and after preparation of intestinal tracts of patients with colorectal cancer prove that the levels of probiotics such as bifidobacterium, lactobacillus and the like of the patients after the operation are obviously reduced. These studies confirm that the scouring effect on the intestinal flora during the preparation of the intestine leads directly to a reduction and a change in the intestinal flora, but at the same time offers the opportunity to reestablish the intestinal micro-ecology of the human body.
In the traditional strategy for repairing the intestinal microecological system, the used microecological preparation cannot ensure the survival rate of probiotics in the intestinal microecological system when the probiotics pass through the gastrointestinal tract, and the recovery and the improvement of the intestinal microecology of the probiotics such as bifidobacterium, lactobacillus and the like after the intestinal tract preparation after the intestinal tract operation are greatly limited. Meanwhile, the contained prebiotics are mostly soluble fructo-oligosaccharides, galacto-oligosaccharides, inulin and the like, the nutritional ingredients are single, the diversity of the nutrient substance basis of the intestinal flora cannot be guaranteed, and the repairing effect is not ideal.
Therefore, there is a need in the art to develop a formulation that combines gut cleansing with restoration/reconstruction/construction of human gut microbiota.
Disclosure of Invention
The invention aims to provide a microecological preparation which can be used for reconstructing intestinal microecology, and can be used for reducing diamine oxidase level, inhibiting intestinal mucosa permeability increase, protecting intestinal mucosa barrier, promoting intestinal tract to exhaust, improving intestinal obstruction or intestinal stalk and/or improving side effects after intestinal tract operation.
The invention provides a microecological preparation, which comprises a strain, sodium alginate, konjac mannan, xylan, L-arabinose and chitosan;
the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the weight ratio of the sodium alginate to the konjac mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (1.5-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjac mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (4-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjac mannan to the xylan to the L-arabinose is (1-3): (0.2-0.4): (5-7): (0.8-1.2).
Preferably, the xylan is arabinoxylan.
Preferably, the probiotic also comprises levan.
Preferably, in the microecological preparation, after the bacterial strain is embedded for the first time by the sodium alginate, the konjac mannan, the xylan and the L-arabinose, the chitosan is used for embedding for the second time.
Preferably, the ratio of said Lactobacillus to said sodium alginate (CFU: g) is 109～1010: 0.1-0.5, preferably 109～1010：0.1-0.3。
Preferably, the ratio of said bifidobacteria to said sodium alginate (CFU: g) is 109～1010: 0.1-0.5, preferably 109～1010：0.1-0.3。
Preferably, the probiotic is prepared by a process comprising the steps of:
(1) mixing sodium alginate, konjac mannan, xylan and L-arabinose with water to obtain polysaccharide solution;
(2) mixing the polysaccharide solution obtained in the step (1) with a bacterial suspension to obtain a bacterial-containing mixed solution, wherein the bacterial suspension contains one or more strains selected from the following groups: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof;
(3) adding the mixed solution containing bacteria obtained in the step (2) into a calcium chloride solution, standing and filtering to obtain a precipitate primary microecological preparation;
(4) and (4) adding the primary microecological preparation obtained in the step (3) into a chitosan solution, and embedding to obtain the microecological preparation.
Preferably, the polysaccharide solution further comprises levan.
Preferably, the sodium alginate is present in the polysaccharide solution in an amount of 0.5 to 10 wt%, preferably 1 to 5 wt%, more preferably 1 to 3 wt%, based on the total weight of the polysaccharide solution.
Preferably, the konjac mannan is contained in the polysaccharide solution in an amount of 0.1 to 0.6 wt%, preferably 0.1 to 0.5 wt%, more preferably 0.2 to 0.4 wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 1 to 10 wt%, preferably 1.5 to 8 wt%, more preferably 5 to 7 wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 2 to 10 wt.%, preferably 4 to 8 wt.%, more preferably 5 to 7 wt.%, based on the total weight of the polysaccharide solution.
Preferably, the amount of L-arabinose in the polysaccharide solution is 0.2 to 2 wt%, preferably 0.5 to 1.5 wt%, more preferably 0.8 to 1.2 wt%, based on the total weight of the polysaccharide solution.
Preferably, the bacterial suspension comprises water.
Preferably, the medium of the bacterial suspension comprises water.
Preferably, the concentration of said lactobacillus in said bacterial suspension is 109～1010CFU/ml。
Preferably, the concentration of said bifidobacteria in said bacterial suspension is 109～1010CFU/ml。
Preferably, in step (2), the volume ratio of the polysaccharide solution to the bacterial suspension is 2-30:1, preferably 5-20: 1, more preferably 5 to 15: 1, optimally 8-12: 1.
preferably, in the step (3), the concentration of the calcium chloride solution is 0.1-0.5mol/L, preferably 0.2-0.4 mol/L.
Preferably, in the step (3), the rest time is 25-35 min.
Preferably, in step (3), the resting temperature is 20-30 ℃.
Preferably, in the step (3), the precipitate is washed with water in the filtering step.
Preferably, in the step (4), the chitosan solution is prepared by the following method:
dissolving chitosan in acetic acid solution, and adjusting pH to 5.5-6.5 to obtain chitosan solution.
Preferably, the concentration of the acetic acid solution is 0.08-0.12 mol/L.
Preferably, the chitosan solution contains chitosan in an amount of 0.05 to 1.2 wt%, preferably 0.1 to 1.0 wt%, more preferably 0.2 to 0.6 wt%, based on the total weight of the chitosan solution.
Preferably, the pH is adjusted with a base.
Preferably, the base is selected from the group consisting of: sodium hydroxide, potassium hydroxide, or a combination thereof.
Preferably, in the step (4), the chitosan solution is prepared by the following method:
dissolving 2.0-6.0g of chitosan by using 900-980mL of 0.08-0.12mol/L acetic acid solution, adjusting the pH value of the solution to 6.0 by using 0.8-1.2mol/L NaOH solution after the chitosan is completely dissolved, and metering to 1000mL after filtering to obtain the chitosan solution.
Preferably, in the step (4), the weight-to-volume ratio (g/ml) of the primary microecological agent to the chitosan solution is 10 to 20: 80-120.
Preferably, in the step (4), the weight ratio of the primary microecological preparation to the chitosan is 10-20: 2-6.
Preferably, in step (4), the embedding comprises a stirring step.
Preferably, the rotation speed of the stirring is 160-200 r/min.
Preferably, the temperature of the stirring is 20-37 ℃.
Preferably, the stirring time is 20-40 min.
Preferably, in step (4), the embedding comprises the steps of:
and (4) adding the primary microecological preparation obtained in the step (3) into a chitosan solution, stirring at constant temperature of 160-37 ℃ for 200r/min for 20-40min, filtering, collecting precipitates, and cleaning with NaCl solution to obtain the microecological preparation.
Preferably, the concentration of the NaCl solution is 8-9.0g/L NaCl.
Preferably, the microecological preparation is a pharmaceutical preparation, a food preparation or a health product preparation.
Preferably, the microecological preparation further comprises other pharmaceutically, food or nutraceutical acceptable carriers.
Preferably, the nutraceutical comprises a dietary supplement.
Preferably, the dosage form of the microecological preparation is an oral preparation.
Preferably, the microecological preparation is tablets, capsules, oral liquid, granules, powder or syrup.
In a second aspect the present invention provides the use of a probiotic according to the first aspect of the invention for the preparation of a composition or formulation for one or more uses selected from the group consisting of: (i) for improving intestinal micro-ecology; (ii) reducing diamine oxidase levels; (iii) inhibiting the increase of intestinal mucosal permeability; (iv) protecting the intestinal mucosal barrier; and/or (vii) ameliorating post-bowel surgery side effects.
Preferably, the improvement comprises reconstruction and/or recovery.
Preferably, said intestinal microbiology comprises a microbiology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the intestinal micro-ecology comprises intestinal micro-ecology after intestinal cleansing and/or intestinal medical surgery.
Preferably, said intestinal micro-ecology comprises intestinal micro-ecology after preparation of the intestine.
Preferably, the intestinal micro-ecology comprises post-intestinal surgery intestinal micro-ecology.
Preferably, the bowel surgery comprises a bowel resection procedure.
Preferably, the bowel surgery comprises a ileocecal enterotomy.
Preferably, the bowel surgery comprises bowel cancer surgery.
Preferably, the cancer comprises rectal cancer, colon cancer or colorectal cancer.
Preferably, the bowel operation comprises bowel surgery performed after bowel preparation.
Preferably, the intestinal micro-ecology comprises post-intestinal surgery intestinal micro-ecology, and the intestinal surgery comprises intestinal surgery performed after intestinal preparation.
Preferably, said bowel preparation comprises bowel preparation of a bowel clearing agent selected from the group consisting of: magnesium sulfate, mannitol, sorbitol, L-arabinose, polyethylene glycol, or a combination thereof.
Preferably, the intestinal surgery comprises rectal cancer surgery, colon cancer surgery or straight/colon cancer surgery.
Preferably, the diamine oxidase level comprises a plasma, serum or whole blood level of diamine oxidase.
Preferably, said inhibiting increased permeability of the intestinal mucosa comprises inhibiting increased permeability of the intestinal mucosa by decreasing levels of diamine oxidase.
Preferably, the diamine oxidase level comprises diamine oxidase levels after intestinal surgery.
Preferably, said protecting the gut mucosal barrier comprises protecting the gut mucosal barrier by inhibiting an increase in gut mucosal permeability.
Preferably, said increased permeability of the intestinal mucosa comprises an increased permeability of the intestinal mucosa following intestinal surgery.
Preferably, the intestinal mucosal barrier comprises an intestinal mucosal barrier after intestinal surgery.
Preferably, said post-operative side effects of the bowel are selected from the group consisting of: intestinal micro-dysbiosis, elevated levels of diamine oxidase, elevated permeability of the intestinal mucosa, disruption of the intestinal mucosal barrier, or a combination thereof.
Preferably, said intestinal microbiology comprises a microbiology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, said intestinal dysbiosis comprises a disorder of microorganisms selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the disorder comprises a decrease (e.g., a decrease in amount).
Preferably, the composition or preparation is a pharmaceutical composition or preparation, a food composition or preparation, or a health product composition or preparation.
Preferably, the composition or preparation further comprises other pharmaceutically, food or nutraceutical acceptable carriers.
Preferably, the nutraceutical comprises a dietary supplement.
Preferably, the composition or the preparation is in the form of an oral preparation.
Preferably, the composition is in the form of tablets, capsules, oral liquid, granules, powder or syrup.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments.
Detailed Description
The invention develops a microecological preparation which can obviously improve the survival rate of microorganisms such as probiotics like lactobacillus and bifidobacterium in gastrointestinal fluid, can obviously improve the recovery and reconstruction of intestinal microecology after intestinal preparation and intestinal operation, improves intestinal microecological imbalance of the intestinal operation, and can improve side effects such as diamine oxidase level increase, intestinal mucosa permeability increase, intestinal mucosa barrier damage and the like. Therefore, the microecologics of the present invention have excellent improving effects on patients with intestinal surgery after intestinal preparation.
Term(s) for
As used herein, the terms "comprising," including, "and" containing "are used interchangeably and include not only open-ended definitions, but also semi-closed and closed-ended definitions, and include" consisting of … …, "" consisting essentially of … ….
The following description of the exemplary embodiments of the present application, including various details of the embodiments of the present application to assist in understanding, should be taken as exemplary only. Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
Microecological preparation
The microecological preparation provided by the invention can restore/rebuild/construct human intestinal microecology after intestinal cleaning. The microecologics preparation can also provide nutrients for the whole intestinal tract probiotics, ensure the diversified nutrient substances required by the colonization and growth of the probiotics in the intestinal tract, promote the growth of the probiotics in the intestinal tract, and recover the functions of participating in metabolic regulation, intestinal tract barrier protection and the like, so that the propagation of harmful intestinal tract bacteria is inhibited while a large amount of microorganisms beneficial to the human health microecologics are preferentially cultured, the aim and the function of recovering/reconstructing/constructing the human microecologics are achieved, and the aim of improving/treating clinical symptoms related to the intestinal tract, such as constipation, diarrhea, abdominal distension and the like, is finally achieved.
The intestinal tract is cleaned by magnesium sulfate, polyethylene glycol or a composition thereof and other medicines, after enteroscopy, probiotics and harmful bacteria originally attached to the surface of the intestinal tract mucosa are discharged along with the clean medicines and cleaning liquid, and the original intestinal tract probiotics have the occupation protection effect of the intestinal tract mucosa and disappear, so that the physical barrier effect of the intestinal tract probiotics is urgently needed to be reestablished. By utilizing the neutral period of gastrointestinal tract emptying (including the period that the original beneficial or harmful bacteria of the intestinal tract are all cleared), the microecological preparation provided by the invention is taken by patients (such as intestinal tract healthy people, constipation people and other people with gastrointestinal tract diseases), can preferentially culture a large amount of microorganisms beneficial to the human health microecology, simultaneously recover intestinal tract probiotics to participate in metabolic regulation such as secretion of intestinal tract mucus, accelerate recovery of damaged intestinal tract mucosa, reduce the permeability of the intestinal tract mucosa to the health level of an individual, and achieve the effect of reconstructing the human intestinal tract microecology.
The invention provides a microecological preparation which comprises a strain, sodium alginate, konjac mannan, xylan, L-arabinose and chitosan;
the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
As used herein, sodium alginate is a by-product after extraction of iodine and mannitol from kelp or gulfweed of brown algae, whose molecules are linked by a (1 → 4) bond of β -D-mannuronic acid (M) and α -L-guluronic acid (α -L-guluronic acid, G), and is a natural polysaccharide, CAS accession no: 9005-38-3.
As used herein, konjac mannan is the main component contained in konjac, CAS accession No.: 37220-17-0. The konjac mannan is white powder, can be swelled with water, and is soluble in water but insoluble in organic solvents such as acetone and chloroform. The konjac mannan is also called konjac flour and konjac gum, and the main components of the konjac mannan are mannan and glucose, and the konjac mannan is white or creamy to light brown yellow powder. Can be used as gelling agent, thickener, emulsifier, stabilizer, and film forming agent.
As used herein, the main chain of xylan is made up of xylose linked via β -1, 4-glycosidic bonds. Typically, the xylan is arabinoxylan. Arabinoxylan is a hemicellulose polysaccharide, is the main existing form of grain or herb cell wall xylan, the macromolecular main chain of the Arabinoxylan is formed by connecting xylose through beta-1, 4-glycosidic bonds, and the branched chain structure contains arabinose substituent groups.
As used herein, L-arabinose, also known as arabinose, fructose; is an aldopentose, CAS accession No.: 5328-37-0.
As used herein, chitosan (chitosan) has many unique properties of biodegradability, cell affinity, and biological effect, among the basic polysaccharides in nature, CAS accession No.: 9012-76-4.
Preferably, the weight ratio of the sodium alginate to the konjac mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (1.5-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjac mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (4-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjac mannan to the xylan to the L-arabinose is (1-3): (0.2-0.4): (5-7): (0.8-1.2).
Preferably, the probiotic also comprises levan.
Preferably, in the microecological preparation, after the bacterial strain is embedded for the first time by the sodium alginate, the konjac mannan, the xylan and the L-arabinose, the chitosan is used for embedding for the second time.
Preferably, the ratio of said Lactobacillus to said sodium alginate (CFU: g) is 109～1010: 0.1-0.5, preferably 109～1010：0.1-0.3。
Preferably, the ratio of said bifidobacteria to said sodium alginate (CFU: g) is 109～1010: 0.1-0.5, preferably 109～1010：0.1-0.3。
In a preferred embodiment of the present invention, the microecological formulation is prepared by a process comprising the steps of:
(1) mixing sodium alginate, konjac mannan, xylan and L-arabinose with water to obtain polysaccharide solution;
(2) mixing the polysaccharide solution obtained in the step (1) with a bacterial suspension to obtain a bacterial-containing mixed solution, wherein the bacterial suspension contains one or more strains selected from the following groups: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof;
(3) adding the mixed solution containing bacteria obtained in the step (2) into a calcium chloride solution, standing and filtering to obtain a precipitate primary microecological preparation;
(4) and (4) adding the primary microecological preparation obtained in the step (3) into a chitosan solution, and embedding to obtain the microecological preparation.
In a preferred embodiment of the present invention, the xylan is arabinoxylan.
Preferably, the polysaccharide solution further comprises levan.
Preferably, the sodium alginate is present in the polysaccharide solution in an amount of 0.5 to 10 wt%, preferably 1 to 5 wt%, more preferably 1 to 3 wt%, based on the total weight of the polysaccharide solution.
Preferably, the konjac mannan is contained in the polysaccharide solution in an amount of 0.1 to 0.6 wt%, preferably 0.1 to 0.5 wt%, more preferably 0.2 to 0.4 wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 2 to 10 wt.%, preferably 4 to 8 wt.%, more preferably 5 to 7 wt.%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 1 to 10 wt%, preferably 1.5 to 8 wt%, more preferably 5 to 7 wt%, based on the total weight of the polysaccharide solution.
In the polysaccharide solution, the content of the L-arabinose is 0.2 to 2 wt%, preferably 0.5 to 1.5 wt%, more preferably 0.8 to 1.2 wt%, based on the total weight of the polysaccharide solution.
Preferably, the bacterial suspension comprises water.
Preferably, the medium of the bacterial suspension comprises water.
Preferably, the concentration of said lactobacillus in said bacterial suspension is 109～1010CFU/ml。
Preferably, the concentration of said bifidobacteria in said bacterial suspension is 109～1010CFU/ml。
Preferably, in step (2), the volume ratio of the polysaccharide solution to the bacterial suspension is 2-30:1, preferably 5-20: 1, more preferably 5 to 15: 1, optimally 8-12: 1.
preferably, in the step (3), the concentration of the calcium chloride solution is 0.1-0.5mol/L, preferably 0.2-0.4 mol/L.
Preferably, in the step (3), the rest time is 25-35 min.
Preferably, in step (3), the resting temperature is 20-30 ℃.
Preferably, in the step (3), the precipitate is washed with water in the filtering step.
Preferably, in the step (4), the chitosan solution is prepared by the following method:
dissolving chitosan in acetic acid solution, and adjusting pH to 5.5-6.5 to obtain chitosan solution.
Preferably, the concentration of the acetic acid solution is 0.08-0.12 mol/L.
Preferably, the chitosan solution contains chitosan in an amount of 0.05 to 1.2 wt%, preferably 0.1 to 1.0 wt%, more preferably 0.2 to 0.6 wt%, based on the total weight of the chitosan solution.
Preferably, the pH is adjusted with a base.
Preferably, the base is selected from the group consisting of: sodium hydroxide, potassium hydroxide, or a combination thereof.
Preferably, in the step (4), the chitosan solution is prepared by the following method:
dissolving 2.0-6.0g of chitosan by using 900-980mL of 0.08-0.12mol/L acetic acid solution, adjusting the pH value of the solution to 6.0 by using 0.8-1.2mol/L NaOH solution after the chitosan is completely dissolved, and metering to 1000mL after filtering to obtain the chitosan solution.
Preferably, in the step (4), the weight-to-volume ratio (g/ml) of the primary microecological agent to the chitosan solution is 10 to 20: 80-120.
Preferably, in the step (4), the weight ratio of the primary microecological preparation to the chitosan is 10-20: 2-6.
Preferably, in step (4), the embedding comprises a stirring step.
Preferably, the rotation speed of the stirring is 160-200 r/min.
Preferably, the temperature of the stirring is 20-37 ℃.
Preferably, the stirring time is 20-40 min.
Preferably, in step (4), the embedding comprises the steps of:
and (4) adding the primary microecological preparation obtained in the step (3) into a chitosan solution, stirring at constant temperature of 160-37 ℃ for 200r/min for 20-40min, filtering, collecting precipitates, and cleaning with NaCl solution to obtain the microecological preparation.
Preferably, the concentration of the NaCl solution is 8-9.0g/L NaCl.
Preferably, the microecological preparation is a pharmaceutical preparation, a food preparation or a health product preparation.
Preferably, the microecological preparation further comprises other pharmaceutically, food or nutraceutical acceptable carriers.
Preferably, the nutraceutical comprises a dietary supplement.
Preferably, the dosage form of the microecological preparation is an oral preparation.
Preferably, the microecological preparation is tablets, capsules, oral liquid, granules, powder or syrup.
Use of
Typically, the present invention provides a use of the probiotic of the present invention for improving intestinal micro-ecology.
In a preferred embodiment of the invention, said intestinal micro-ecology comprises a microbial ecology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the intestinal micro-ecology comprises intestinal micro-ecology after intestinal cleansing and/or intestinal medical surgery.
Preferably, said intestinal micro-ecology comprises intestinal micro-ecology after preparation of the intestine.
Preferably, the intestinal micro-ecology comprises post-intestinal surgery intestinal micro-ecology.
Preferably, the bowel surgery comprises a bowel cancer surgery, for example, an open radical colon/rectal cancer resection.
Preferably, the cancer comprises rectal cancer, colon cancer or colorectal cancer.
Preferably, the bowel surgery comprises a bowel resection procedure.
Preferably, the bowel surgery comprises a ileocecal enterotomy.
Typically, the bowel surgery comprises bowel surgery performed after bowel preparation.
Typically, the intestinal micro-ecology comprises post-intestinal surgery intestinal micro-ecology, and the intestinal surgery comprises intestinal surgery performed after intestinal preparation.
Preferably, said bowel preparation comprises bowel preparation of a bowel clearing agent selected from the group consisting of: magnesium sulfate, mannitol, sorbitol, L-arabinose, polyethylene glycol, or a combination thereof.
Preferably, the intestinal surgery comprises rectal cancer surgery, colon cancer surgery or straight/colon cancer surgery.
In another preferred embodiment of the present invention, the present invention provides a use of the probiotic of the present invention for reducing diamine oxidase levels; inhibiting the increase of intestinal mucosal permeability; protecting the intestinal mucosal barrier; and/or improving side effects after intestinal surgery.
Preferably, the diamine oxidase level comprises a plasma, serum or whole blood level of diamine oxidase.
Preferably, said inhibiting increased permeability of the intestinal mucosa comprises inhibiting increased permeability of the intestinal mucosa by decreasing levels of diamine oxidase.
Preferably, the diamine oxidase level comprises diamine oxidase levels after intestinal surgery.
Preferably, said protecting the gut mucosal barrier comprises protecting the gut mucosal barrier by inhibiting an increase in gut mucosal permeability.
Preferably, said increased permeability of the intestinal mucosa comprises an increased permeability of the intestinal mucosa following intestinal surgery.
Preferably, the intestinal mucosal barrier comprises an intestinal mucosal barrier after intestinal surgery.
Preferably, said post-operative side effects of the bowel are selected from the group consisting of: intestinal micro-dysbiosis, elevated levels of diamine oxidase, elevated permeability of the intestinal mucosa, disruption of the intestinal mucosal barrier, or a combination thereof.
Preferably, said intestinal microbiology comprises a microbiology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, said intestinal dysbiosis comprises a disorder of microorganisms selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the disorder comprises a decrease (e.g., a decrease in amount).
Composition comprising a metal oxide and a metal oxide
The invention also provides a composition which can be a pharmaceutical composition, a food composition or a health-care product composition.
The composition also comprises a carrier acceptable in pharmacy, food or health care products.
As used herein, the term "pharmaceutically, comestibly or nutraceutically acceptable carrier" refers to: one or more compatible solid, semi-solid, liquid or gel fillers suitable for human or animal use and of sufficient purity and sufficiently low toxicity.
It is to be understood that, in the present invention, the carrier is not particularly limited and may be selected from materials commonly used in the art, or prepared by a conventional method, or commercially available. Examples of the pharmaceutically acceptable carrier moiety are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, etc.), polyols (e.g., propylene glycol, glycerin, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium laurylsulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal enhancers, colorants, flavors, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.
In the present invention, the dosage form of the pharmaceutical composition includes (but is not limited to) oral formulations.
Representative dosage forms include (but are not limited to): tablet, capsule, oral liquid, granule, powder or syrup.
The main technical effects obtained by the invention comprise:
1. the invention develops a microecological preparation which can obviously improve the survival rate of microorganisms such as lactobacillus, bifidobacterium and other probiotics in gastrointestinal fluid.
2. The microecological preparation can remarkably improve the recovery and reconstruction of intestinal microecology after intestinal operation through intestinal preparation, improve the intestinal microecological imbalance of the intestinal operation, and improve the side effects of diamine oxidase level increase, intestinal mucosa permeability increase, intestinal mucosa barrier damage and the like. Therefore, the microecologics of the present invention have excellent improving effects on patients with intestinal surgery after intestinal preparation.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
EXAMPLE 1 Microecological preparation
This example provides a method for preparing a probiotic, said method comprising the steps of:
1. activation of strains and preparation of concentrated bacterial suspension
All glassware and solutions were sterilized at 121 ℃ for 20 min. Inoculating the frozen strain (Bifidobacterium) into MRS liquid culture medium, culturing at 37 deg.C for 24 hr, and subculturing for several times until the strain is completely activated. Centrifuging the culture solution at the last logarithmic phase for 8-12 min at 4 ℃, pouring out the supernatant, washing the bacterial sludge twice with sterile normal saline, and then re-suspending the bacterial sludge in sterile water to obtain a concentrated bacterial suspension, wherein the bacterial concentration of bifidobacterium in the bacterial suspension is 109～1010CFU/ml。
2. Preparation of primary microecological preparation
Mixing sodium alginate, konjac mannan, arabinoxylan and L-arabinose with water to obtain a polysaccharide mixed solution, wherein the contents of the sodium alginate, the konjac mannan, the arabinoxylan and the L-arabinose are respectively 2 wt%, 0.3 wt%, 6 wt% and 1 wt%, based on the total weight of the polysaccharide mixed solution. Sterilizing the polysaccharide mixed solution at 121 deg.C for 20min, and cooling to room temperature. And (2) uniformly mixing the bacterial suspension obtained in the step (1) with the polysaccharide mixed solution according to the volume ratio of 1:10, then extruding into 0.3mol/L calcium chloride solution by using an injector, standing at the room temperature of 25 ℃ for 30min, filtering, and washing for 2 times by using sterile water to obtain the primary microecological preparation of the precipitate.
3. Preparation of microecological preparation
Dissolving 4.0g of chitosan by using 950mL of 0.1mol/L acetic acid solution, adjusting the pH value of the solution to 6.0 by using 1.0mol/L NaOH solution after the chitosan is completely dissolved, and carrying out filtration and constant volume to 1000mL to obtain the chitosan solution. And (3) adding 15.0g of the primary microecological preparation prepared in the step (2) into 100mL of prepared chitosan solution, stirring at the constant temperature of 37 ℃ for 30min at 180r/min, filtering by using gauze to collect the secondary embedded microecological preparation, cleaning twice by using sterile 8.5g/L NaCl solution, and then carrying out low-temperature freeze drying to obtain the microecological preparation.
EXAMPLE 2 Microecological preparation
This example provides a method for preparing a probiotic, said method comprising the steps of:
1. activation of strains and preparation of concentrated bacterial suspension
The same procedure as in step 1 of example 1 was followed.
2. Preparation of primary microecological preparation
Mixing sodium alginate with water to obtain sodium alginate solution, wherein the content of sodium alginate is 2 wt%, sterilizing at 121 deg.C for 20min, and cooling to room temperature. And (2) uniformly mixing the bacterial suspension obtained in the step (1) with a sodium alginate solution according to a volume ratio of 1:10, extruding into a 0.3mol/L calcium chloride solution by using an injector, standing for 30min at the room temperature of 25 ℃, filtering, and washing for 2 times by using sterile water to obtain the primary microecological preparation of the precipitate.
3. Preparation of microecological preparation
The same procedure as in step 3 of example 1 was carried out to prepare a microecological preparation.
EXAMPLE 3 Microecological preparation
This example provides a method for preparing a probiotic, said method comprising the steps of:
1. activation of strains and preparation of concentrated bacterial suspension
The same procedure as in step 1 of example 1 was followed.
2. Preparation of primary microecological preparation
Mixing konjac mannan, arabinoxylan and L-arabinose with water to obtain a polysaccharide mixed solution, wherein the content of the konjac mannan, the content of the arabinoxylan and the content of the L-arabinose are respectively 0.3 wt%, 6 wt% and 1 wt%, based on the total weight of the polysaccharide mixed solution. Sterilizing the polysaccharide mixed solution at 121 deg.C for 20min, and cooling to room temperature. And (2) uniformly mixing the bacterial suspension obtained in the step (1) with a polysaccharide solution according to the volume ratio of 1:10, extruding into a 0.3mol/L calcium chloride solution by using an injector, standing for 30min at the room temperature of 25 ℃, filtering, and washing for 2 times by using sterile water to obtain the primary microecological preparation of the precipitate.
43. Preparation of microecological preparation
The same procedure as in step 3 of example 1 was carried out to prepare a microecological preparation.
Effect experiment example 1
The effect experimental example investigates the influence of different embedding methods on the survival rate of the bifidobacteria
Preparation of the test: artificial gastric juice/high salt bile preparation
(1) Preparation of artificial gastric juice: preparing artificial gastric juice containing 3% pepsin and 2% NaCl and having a pH value of 2.0, filtering the prepared artificial gastric juice through a 0.22-micron membrane for sterilization, and placing the sterilized artificial gastric juice in a refrigerator for later use.
(2) Preparing artificial small intestine solution: preparing an artificial intestinal juice containing 1% pancreatin and having a pH value of 6.8, filtering the prepared artificial intestinal juice through a 0.22 mu m membrane for sterilization, and placing the artificial intestinal juice in a refrigerator at 4 ℃ for later use.
(3) Preparing a high-bile salt solution: dispersing bile salt in phosphate buffer solution uniformly to make its final concentration be 2g/L, then using 0.1mol/L NaOH solution to regulate pH value of said mixed liquor to 6.8, filtering and sterilizing, placing in refrigerator for stand-by.
The test process comprises the following steps:
9mL of the prepared artificial gastric juice, the prepared artificial small intestine juice and the prepared high bile salt solution are respectively taken, 1g of the microecological preparation or the primary microecological preparation prepared in the examples 1-3 is respectively added, the mixture is taken out by shaking the table at the temperature of 37 ℃ for 120min at 180r/min, viable bacteria are counted, and meanwhile, the comparison with the bacterial suspension (1m L) is carried out, and the results are shown in the table 1:
table 1 effect of different formulations on survival of bifidobacteria (n ═ 3, mean)
Figure BDA0002784896070000151
Figure BDA0002784896070000161
As can be seen from Table 1, the probiotic preparations prepared in examples 1-3 were able to increase the survival rate of Bifidobacterium in gastrointestinal fluids, thereby prolonging the survival time of Bifidobacterium in gastrointestinal fluids.
Effect experiment example 2
The effect experimental example investigates the improvement effect of the microbial flora of the microecologics after the preparation of the intestinal tract
1. The test method comprises the following steps:
selecting healthy SD rats, self-adapting for one week after purchase, then randomly dividing the SD rats into 5 groups, wherein each group comprises 8 rats, each male and female half are respectively an experimental group 1, an experimental group 2, an experimental group 3, an experimental group 4 and a control group, the rats of the experimental group 1, the experimental group 2, the experimental group 3 and the experimental group 4 are gastrically infused on the 1 st day and are provided with 33 wt% magnesium sulfate solution (the administration dosage of magnesium sulfate is 10ml/kg) for intestinal tract preparation, fasting is not forbidden, the rats of the experimental groups 1-4 are respectively operated on the 2 nd morning, and the operation process is as follows: after anesthesia with 2% sodium pentobarbital 5ml/kg, a 1cm section of intestine was excised 5cm proximal to the ileocecal area and injected subcutaneously with 5% saline 50 ml/kg.
On days 1 to 5 after the operation, rats of experimental group 1, experimental group 2, and experimental group 3 were each gavaged with physiological saline to deliver the probiotics prepared in examples 1 to 3Formulation (experimental groups 1-3 bifidobacteria per rat administered at a dose of 3.5 x 107CFU count/220 g. body weight), rats of experimental group 4 were gavaged with normal saline and had free diet. The control group SD rats were fed a normal diet without any magnesium sulfate intestinal preparation and surgical treatment, and served as a blank control.
On day 6 after surgery, each group of rats was sacrificed after tail-cutting and blood-drawing, and 1g of the cecum feces were collected for bacterial culture.
The administration mode of each experimental group is as follows:
experimental group 1: preparation of the intestine and post-operative administration of the probiotic prepared in example 1;
experimental group 2: preparation of the intestine and post-operative administration of the probiotic prepared in example 2;
experimental group 3: preparation of the intestine and post-operative administration of the probiotic prepared in example 3;
experimental group 4: preparation of the intestine and administration of saline after surgery;
control group: SD rats were not treated at all and were on a normal diet.
Observations and index measurements were as follows:
(1) and (3) analyzing intestinal flora: selecting a culture medium: the bifidobacterium adopts a BS blood agar plate, the bifidobacterium strains are identified and counted according to a plate viable count method, and the logarithmic value of Colony Forming Unit (CFU) in the wet weight of each gram of feces is calculated.
(2) Determination of serum diamine oxidase (DAO) level as indicator of intestinal mucosal permeability
Carrying out orbital bleeding on rats of each group 1 day before preparation of magnesium sulfate intestinal tracts, centrifuging to obtain serum, and measuring the serum diamine oxidase (DAO) level of rats of each group before an experiment;
on the 6 th day after operation, each group of rats is cut off the tail and bled, and centrifuged to obtain serum, and the level of serum diamine oxidase (DAO) is measured;
serum diamine oxidase (DAO) levels were determined using an enzyme-linked immunosorbent assay.
Statistical method
Statistical treatment all data were statistically analyzed using SPSS18..0, and counted using a t-testData adoption chi2And the difference is statistically significant when P is less than or equal to 0.05.
2. Test results
Changes in intestinal flora in the blind feces taken on day 6 after surgery in different groups of SD rats are shown in table 2.
TABLE 2 intestinal flora of different groups of SD rats on day 6 post-surgery (mean. + -. SD, lgCFU/g)
Group of Bifidobacterium
Control group 8.45±0.79
Experimental group 1 7.86±0.63**
Experimental group 2 6.22±0.54*
Experimental group 3 6.61±0.58**
Experimental group 4 5.77±0.47**
Note: p <0.05, p <0.01 compared to control.
As can be seen from table 2, the probiotics prepared in examples 1 to 3 were effective in improving the rapid recovery of the intestinal bifidobacterium flora, compared to the control group. And as can be seen from the data of the experimental groups 1-3, the sodium alginate, the konjac mannan, the xylan, the L-arabinose and the chitosan can synergistically improve the recovery of the intestinal flora.
The change in serum diamine oxidase (DAO) levels in SD rats of different groups on day 1 before (before experiment) and day 6 after (after experiment) magnesium sulfate intestinal preparation is shown in Table 3
TABLE 3 different groups of SD rats diamine oxidase (DAO) levels (mean. + -. SD, pg/ml) in serum 1 day before (pre-experiment) and 6 days after (post-experiment) preparation of the magnesium sulfate intestine
Group of Magnesium sulfate 1 day before intestinal tract preparation Day 6 after surgery
Control group 0.74±0.04 0.76±0.06
Experimental group 1 0.76±0.03 0.85±0.05**
Experimental group 2 0.73±0.05 1.06±0.07**
Experimental group 3 0.76±0.06 0.99±0.07*
Experimental group 4 0.76±0.06 1.16±0.07**
Note: p <0.05, p <0.01, compared to day 6 after surgery in the control group.
Intestinal tract resection after intestinal tract preparation easily causes the permeability of intestinal mucosa to rise, thereby destroying the barrier function of the intestinal mucosa, and diamine oxidase (DAO) in serum is an index of the permeability of the intestinal mucosa. As can be seen from the experimental groups 1-4 in Table 3, the level of diamine oxidase (DAO) in the post-enterotomy serum was increased after the preparation of the intestine, indicating that the post-enterotomy increased the permeability of the intestinal mucosa and destroyed the barrier function of the intestinal mucosa. Compared with the experimental group 4 (intestinal tract preparation and physiological saline administration after operation), the rise amplitude of diamine oxidase (DAO) in serum of the experimental groups 1-3 is obviously smaller than that of the experimental group 4, especially the rise amplitude of the experimental group 1 is obviously reduced, which shows that the microecological preparation administered by the experimental groups 1-3 can obviously inhibit the increase of mucosal permeability caused by intestinal tract resection after the intestinal tract preparation, thereby effectively protecting the intestinal mucosal barrier.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims (10)

1. A microecological preparation is characterized in that the microecological preparation comprises strains, sodium alginate, konjac mannan, xylan, L-arabinose and chitosan;
the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
2. The microecological agent according to claim 1, wherein the weight ratio of sodium alginate, konjac mannan, xylan and L-arabinose is (1-5): (0.1-0.5): (1.5-8): (0.5-1.5).
3. The microecological agent according to claim 1, wherein the microecological agent comprises a first bacterial seed coating with sodium alginate, konjac mannan, xylan and L-arabinose, followed by a second coating with chitosan.
4. The probiotic of claim 1, wherein said xylan is an arabinoxylan.
5. The microecological formulation of claim 1, wherein the microecological formulation is prepared by a process comprising the steps of:
(1) mixing sodium alginate, konjac mannan, xylan and L-arabinose with water to obtain polysaccharide solution;
(2) mixing the polysaccharide solution obtained in the step (1) with a bacterial suspension to obtain a bacterial-containing mixed solution, wherein the bacterial suspension contains one or more strains selected from the following groups: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof;
(3) adding the mixed solution containing bacteria obtained in the step (2) into a calcium chloride solution, standing and filtering to obtain a precipitate primary microecological preparation;
(4) and (4) adding the primary microecological preparation obtained in the step (3) into a chitosan solution, and embedding to obtain the microecological preparation.
6. The microecological formulation according to claim 5, wherein the sodium alginate is present in the polysaccharide solution in an amount of 0.5 to 10 wt.%, preferably 1 to 5 wt.%, more preferably 1 to 3 wt.%, based on the total weight of the polysaccharide solution;
in the polysaccharide solution, the content of the konjac mannan is 0.1-0.6 wt%, preferably 0.1-0.5 wt%, more preferably 0.2-0.4 wt%, based on the total weight of the polysaccharide solution;
in the polysaccharide solution, the content of the xylan is 1 to 10 wt%, preferably 1.5 to 8 wt%, more preferably 5 to 7 wt%, based on the total weight of the polysaccharide solution; and/or
In the polysaccharide solution, the content of the L-arabinose is 0.2 to 2 wt%, preferably 0.5 to 1.5 wt%, more preferably 0.8 to 1.2 wt%, based on the total weight of the polysaccharide solution.
7. The probiotic according to claim 5, characterized in that said lactic acid bacteria are present in said bacterial suspension at a concentration of 109～1010CFU/ml; andor or
In the bacterial suspension, the concentration of the bifidobacteria is 109～1010CFU/ml。
8. The microecological formulation according to claim 5, wherein in step (2), the volume ratio of the polysaccharide solution to the bacterial suspension is 2-30:1, preferably 5-20: 1, more preferably 5 to 15: 1, optimally 8-12: 1.
9. the microecological agent according to claim 5, wherein the chitosan is present in the chitosan solution in an amount of 0.05 to 1.2 wt%, preferably 0.1 to 1.0 wt%, more preferably 0.2 to 0.6 wt%, based on the total weight of the chitosan solution.
10. Use of the probiotic according to claim 1, for the preparation of a composition or preparation for one or more uses selected from the group consisting of: (i) for improving intestinal micro-ecology; (ii) reducing diamine oxidase levels; (iii) inhibiting the increase of intestinal mucosal permeability; (iv) protecting the intestinal mucosal barrier; and/or (v) ameliorating post-bowel surgery side effects.
CN202011294300.7A 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology Active CN112370470B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011294300.7A CN112370470B (en) 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011294300.7A CN112370470B (en) 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology

Publications (2)

Publication Number Publication Date
CN112370470A true CN112370470A (en) 2021-02-19
CN112370470B CN112370470B (en) 2023-05-26

Family

ID=74584209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011294300.7A Active CN112370470B (en) 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology

Country Status (1)

Country Link
CN (1) CN112370470B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112401242A (en) * 2020-11-18 2021-02-26 复旦大学附属中山医院 Microecological preparation for reconstructing intestinal microecology and application thereof
CN113854569A (en) * 2021-08-25 2021-12-31 河北天烨食品科技有限公司 Probiotic nutrient, preparation method thereof and method for improving survival rate of edible probiotics
CN114698729A (en) * 2022-03-30 2022-07-05 播恩集团股份有限公司 Microecological preparation containing 5-methyltetrahydrofolic acid and preparation method and application thereof
CN114917292A (en) * 2022-05-31 2022-08-19 湖南航天医院 Intestinal microecological preparation for preventing and treating intestinal inflammatory diseases
CN115024374A (en) * 2022-06-15 2022-09-09 黄淮学院 Preparation method and application of candy containing immobilized probiotics
CN115227728A (en) * 2022-05-31 2022-10-25 湖南航天医院 Intestinal microecological preparation and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104887647A (en) * 2014-03-08 2015-09-09 复旦大学 Probiotics double-layered microcapsule and manufacturing method thereof
CN105188643A (en) * 2013-02-25 2015-12-23 欧莱雅 Gel-type cosmetic composition
CN109528683A (en) * 2018-12-13 2019-03-29 浙江华康药业股份有限公司 A kind of arabinose fixed point release produces the regulation method of butyric to enteral
US20200108105A1 (en) * 2017-04-13 2020-04-09 CosmoLab LLC. Microcapsules containing live microorganisms and use thereof
CN111671791A (en) * 2020-05-25 2020-09-18 中山大学 Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188643A (en) * 2013-02-25 2015-12-23 欧莱雅 Gel-type cosmetic composition
CN104887647A (en) * 2014-03-08 2015-09-09 复旦大学 Probiotics double-layered microcapsule and manufacturing method thereof
US20200108105A1 (en) * 2017-04-13 2020-04-09 CosmoLab LLC. Microcapsules containing live microorganisms and use thereof
CN109528683A (en) * 2018-12-13 2019-03-29 浙江华康药业股份有限公司 A kind of arabinose fixed point release produces the regulation method of butyric to enteral
CN111671791A (en) * 2020-05-25 2020-09-18 中山大学 Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
史艳莉等: "魔芋甘露聚糖对大负荷训练大鼠肠道微生态的影响", 《湖北大学学报（自然科学版）》 *
吴小嫚等: "复合法制备嗜酸乳杆菌－双歧杆菌益生菌微胶囊饲料工艺及体外消化特性研究", 《动物营养学报》 *
姚泽晨等: "植物乳杆菌微胶囊包载效果、物化性质及其胃肠道性能", 《食品工业科技》 *
黄莹等: "肠道菌群失衡与急性胰腺炎易位感染的关系", 《中国微生态学杂志》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112401242A (en) * 2020-11-18 2021-02-26 复旦大学附属中山医院 Microecological preparation for reconstructing intestinal microecology and application thereof
CN112401242B (en) * 2020-11-18 2023-07-25 复旦大学附属中山医院 Microecological preparation for reconstructing intestinal microecology and application thereof
CN113854569A (en) * 2021-08-25 2021-12-31 河北天烨食品科技有限公司 Probiotic nutrient, preparation method thereof and method for improving survival rate of edible probiotics
CN114698729A (en) * 2022-03-30 2022-07-05 播恩集团股份有限公司 Microecological preparation containing 5-methyltetrahydrofolic acid and preparation method and application thereof
CN114698729B (en) * 2022-03-30 2023-01-10 播恩集团股份有限公司 Microecological preparation containing 5-methyltetrahydrofolic acid and preparation method and application thereof
CN114917292A (en) * 2022-05-31 2022-08-19 湖南航天医院 Intestinal microecological preparation for preventing and treating intestinal inflammatory diseases
CN115227728A (en) * 2022-05-31 2022-10-25 湖南航天医院 Intestinal microecological preparation and preparation method thereof
CN115024374A (en) * 2022-06-15 2022-09-09 黄淮学院 Preparation method and application of candy containing immobilized probiotics
CN115024374B (en) * 2022-06-15 2023-11-24 黄淮学院 Preparation method and application of candy containing immobilized probiotics

Also Published As

Publication number Publication date
CN112370470B (en) 2023-05-26

Similar Documents

Publication Publication Date Title
CN112370470B (en) Microecological preparation for reconstructing intestinal microecology
AU2004228936B2 (en) Synbiotic combination
Chow Probiotics and prebiotics: a brief overview
KR101493302B1 (en) Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
JP5498698B2 (en) New uses of white jellyfish miscellaneous polysaccharides or their extracts
US20040086491A2 (en) Probiotic/Prebiotic Composition and Delivery Method
BRPI0314060B1 (en) a composition comprising lactobacillus fermentum variant or variant component and uses of the lactobacillus fermentum variant or variant component and composition
CN109419816B (en) Application of bacteroides cellulolyticus in preventing and/or treating heart diseases
CN114404445B (en) Application of cyclodextrin in preparation of medicine for treating ulcerative colitis
JPH03151854A (en) Composition for improving intestinal environment
KR20040037011A (en) Food Composition Containing a Lactic Acid Bacteria
JP4054697B2 (en) Constipation improving agent
CN112401242B (en) Microecological preparation for reconstructing intestinal microecology and application thereof
CN105343132B (en) Composition, the drug and preparation method thereof for treating colitis
CN110448569B (en) Composition with antidiarrheal effect, preparation method and application thereof
AU2012221154B2 (en) Indirect substrates for microorganisms metabolizing 1,2-propanediol
CN115177642B (en) Composition for regulating intestinal flora of ulcerative colitis and preparation method and application thereof
EP2486931A1 (en) Therapeutic agent for influenza virus infectious diseases
CN111265627B (en) Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof
KR101842041B1 (en) Purgative composition
CN115192602A (en) Composite prebiotics and application thereof in regulating intestinal function
CN115666276A (en) Fiber blend formulations and uses thereof
WO2004067037A1 (en) Intestinal environment controlling agent for oral use and normal intestinal flora growing kit for oral use
EP4088726A1 (en) Composition for use in preventing or treating diarrhea, constipation or irritable bowel syndrome with fibers formed of beta-1-4-glucan
CN115737599A (en) Colorectal-release intestinal bacterium microcapsule

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant